Ronald Swerdloff, MD

Ronald Swerdloff, MD

Investigator, The Lundquist Institute
Division of Endocrinology, Harbor-UCLA Medical Center
Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA


Male Reproductive Medicine and Biology; Androgen Drug Development; Protective Effects of the Peptide Humanin; Epigenetics of Exercise and Diet

Research Description

Dr. Swerdloff’s research includes basic investigations, clinical trials, and translational studies. His research interests involve many aspects of basic male reproductive physiology and clinical reproductive investigation. Ongoing work includes the regulation of spermatogenesis, regulation of the androgen receptor gene, neuroregulation of gonadotropin secretion, development of male contraceptive agents, pharmacology of androgen hormones, regulation of spermatogenesis, hormonal function in the testis, ethnic differences in the reproductive endocrine system, role of 5-alpha reduced androgens in the prevention and treatment of cognitive dysfunction, sexual dysfunction, impaired vitality, osteoporosis and frailty in elderly men, factors influencing male fertility, molecular basis of Klinefelter's Syndrome, and mutant mouse models in reproductive biology, stem cell transplantation in the testes. Studies on epigenetic modification of gene transcription and RNA translation. protection of normal tissue from the adverse effects of chemotherapy.
Theme Groups


  • MD, 1962, University of California, San Francisco

Recent and/or Significant Publications

Jia Y, Yee JK, Wang C, Nikolaenko L, Cohen J, French S, Lue YH, Lee WN, Swerdloff RS. Testosterone and Non-Alcoholic Fatty Liver Disease--Friend or Foe, Endo2017 Florida April 2017.
Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105(8):dgaa238. doi:10.1210/clinem/dgaa238
Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020;12:1756287220937232. Published 2020 Jun 30. doi:10.1177/1756287220937232
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER, 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi:10.1056/NEJMoa1506119
Yuen F, Wu S, Thirumalai A, Swerdloff RS, Page ST, Liu PY, Dart C, Wu H, Blithe DL, Sitruk-Ware R, Long J, Bai F, Hull L, Bremner WJ, Anawalt BD, Wang C. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology. 2019 Mar;7(2):235-243.


Ronald Swerdloff MD Discusses Chemotherapy Side Effects